Green Immunology

Green Immunology is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of next-generation immunotherapies for cancer and infectious diseases. The company primarily focuses on T-cell receptor (TCR) based technologies, including TCR-engineered T-cell (TCR-T) therapies and soluble TCR-based bispecific biologics. Its lead candidate, GIM-101, is a TCR-T therapy targeting the NY-ESO-1 antigen, currently being evaluated in clinical trials for synovial sarcoma and other solid tumors. Green Immunology utilizes a proprietary platform for high-affinity TCR discovery and optimization to target intracellular tumor antigens that are inaccessible to traditional antibody therapies. By integrating advanced cell engineering and manufacturing capabilities, the company aims to provide curative treatments for patients with refractory malignancies.